Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine D... ( ROCKVILLE Md. May 22 /- Novavax I...)

Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

Date:5/22/2008

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology.

"Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex infectious disease targets because many of these biological structures do not assemble efficiently," said Dr. Gale Smith, Vice President, Vaccine Development. "Our new proprietary process uses select components of SARS and other structural proteins that combine with cell membranes to form distinctive SARS coronavirus nanoparticles, which are nearly identical to the human SARS virus but lack the genetic material needed to replicate and cause disease."

"This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world," said Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus and was first reported in Asia in February 2003. According to the World Health Organization (WHO), subsequent to the 2003 breakout, over 8,000 people were infected, with 774 reported deaths. While there is currently no known reported SARS transmission globally, WHO and other such agencies continue to monitor the SARS situation on a global basis as health officials remain concerned that SARS or similar disease could reemerge.

The SARS VLP program is conducted under an NIH grant. Novavax does not have the commercial rights to this product candidate.

About Novavax '/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
2. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
3. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
4. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
5. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
6. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
7. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
8. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
9. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
10. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
11. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy

Post Your Comments:

(Date:2/9/2010)... Volcano Corporation (Nasdaq: VOLC ), ... therapy guidance tools designed to enhance the diagnosis ... announced today that it has received 510(k) clearance ... to market the Eagle Eye® Platinum digital IVUS ... state-of-the-art catheter offers all of the benefits of ...

(Date:2/9/2010)... of procedures with high radiation doses ,, ... The U.S. Food and Drug ... radiation exposure from three types of medical imaging ... fluoroscopy. These procedures are the greatest contributors to ... use much higher radiation doses than other radiographic ...

(Date:2/9/2010)... Feb. 9 ISTA Pharmaceuticals, Inc. ... for the full year 2010. The Company expects ... $165 million . In addition, ISTA,s management anticipates ... earnings per share for the full year expected ... any mark-to-market adjustments relating to warrants. ,, ...

Breaking Medicine Technology:Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 2 Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 3 Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 4 FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging 2 FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging 3 FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging 4 ISTA Pharmaceuticals Announces 2010 Financial Guidance 2 ISTA Pharmaceuticals Announces 2010 Financial Guidance 3 ISTA Pharmaceuticals Announces 2010 Financial Guidance 4 ISTA Pharmaceuticals Announces 2010 Financial Guidance 5 HIV integrase inhibitor effective for patients beginning antiretroviral treatment 53437 1 HIV integrase inhibitor effective for patients beginning antiretroviral treatment 53437 2 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 1 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 2 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 3 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 4 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 5 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 6 Purdue Pharmaceutical Products L P and Transcept Pharmaceuticals Inc Sign Exclusive Agreement to Commercialize Intermezzo 28R 29 in the United Stat 13317 7 Scientists learn why even treated genital herpes sores boost the risk of HIV infection 53432 1 Scientists learn why even treated genital herpes sores boost the risk of HIV infection 53432 2 Scientists learn why even treated genital herpes sores boost the risk of HIV infection 53432 3 Scientists learn why even treated genital herpes sores boost the risk of HIV infection 53432 4

[0] Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter [0] FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging [0] ISTA Pharmaceuticals Announces 2010 Financial Guidance

... YORK, June 24 Intellect Neurosciences,Inc. (OTC Bulletin ... have achieved an important milestone through their collaborative,efforts ... creating,a therapeutic antibody for the treatment of Alzheimer,s ... promote clearance from the brain of beta,amyloid, the ...

... Expert Offers Tips for Benefits/HR Managers, DALLAS, ... departments can play an important role in preventing ... according to a,leading prevention expert at U.S. Preventive ... Lyles, corporate medical director at U.S. Preventive Medicine,says ...

Other Medicine Technology:Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody 2 Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody 3 Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody 4 Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody 5 U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks 2 U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks 3

Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks

(Date:2/9/2010)... prematurely in the US, according to data presented by ... were reported at the 30th Annual Meeting of the ... published in the latest issue of the American ... that CP is associated with inflammation of the connective ... common in premature births from preterm labor and premature ...

(Date:2/9/2010)... America, millions find themselves whacked-out on powerful prescription drugs to ... a former extreme anxiety sufferer shows natural ways to find ... ... (PRWEB) February 9, 2010 -- Over 40 million Americans suffer ... of society,s garden-variety worriers . Typical anxiety treatment includes ...

(Date:2/9/2010)... warn of Torsade de Pointes in new scientific ... Doctors and other health-care professionals need to be ... potentially deadly heart rhythm problem called Torsade de ... the American Heart Association and the American College ... with a drop in blood pressure that can ...

(Date:2/9/2010)... Feb. 9 Alan Revell of ... a nursing home before he quit. What he witnessed was the ... Annandale . ,, "I just knew that there had to be ... President/CEO of Caring Rose Home Care. "What I saw in just ... respectable nursing homes, but I knew right then that we needed ...

(Date:2/9/2010)... Military brass support improved school nutrition to cut obesity, ... Feb. 9 General Johnnie E. ... Norman Seip , U.S. Air Force (Ret.), said Tuesday ... security, noting that being overweight has become the Number ... in the armed services. The generals, comments came in ...

Breaking Medicine News(10 mins):Health News:Incidence of cerebal palsy on rise in United States 2 Health News:Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy 2 Health News:ICU Patients at Risk for Rare Heart Rhythm Problem 2 Health News:Caring Rose Home Care Launched To Help Seniors Live Independently 2 Health News:Retired Military Brass Support First Lady's Call to Reduce Child Obesity, Improve Nutrition 2

[0] Incidence of cerebal palsy on rise in United States [0] Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy [0] ICU Patients at Risk for Rare Heart Rhythm Problem [0] Caring Rose Home Care Launched To Help Seniors Live Independently [0] Retired Military Brass Support First Lady's Call to Reduce Child Obesity, Improve Nutrition

... &,Gamble Company (NYSE: PG ) announced net sales growth ... billion. Organic sales were up five,percent, delivering at the mid-point ... was led by strong growth in the Beauty, Fabric,Care & ... net earnings,per share increased 12 percent to $1.03 for the ...

... at subclinical level and in early lactation ... would benefit producers, ... and diagnosing mastitis in dairy cows are not serving the,needs of ... at the recent annual meeting of the American,Association of Bovine Practitioners ...

... - GAAP diluted earnings per share from continuing operations decline 16 ... non-GAAP basis ... ... Health, a,global provider of products and services that improve the safety and,productivity of ...

... could you do with,$150,000? That,s the sum the ... for Gov. Sarah Palin., Contrast that with ... scrubs,for just $10 for a hospital shift. "The ... Geri Jenkins, RN, co-president of the California,Nurses Association/National ...

... smiles for Californians, Ron Greenspan, DDS, has been selected for the 2008 ... D.C. based U.S. Local Business Association (USLBA). , ... San Diego (PRWEB) ... Californians, Ron Greenspan, DDS, has been selected for the 2008 Best of ...

... the global fluoroscopy and mobile C-arms market is forecast to crawl ... a large chunk of total market, particularly in the developed world. ... , ... San Jose, CA (PRWEB) October 29, 2008 ...

P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth Dairy Veterinarians Highlight Need for Improved Methods for Detecting Mastitis Cardinal Health Reports First Quarter Results Nurses Present Palin Clothing Line Website ... and Other Ways the Money Could Have Been Spent Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts

... ImmunoWELL VCA IgM Test is an ELISA method ... Epstein-Barr Virus viral capsid antigen (VCA) in human ... in conjunction with other testing such as the ... early antigen tests and/or heterophile tests, the results ...

... Tests are qualitative enzyme immunoassays (EIA) for ... (IgG or IgM, respectively) in serum. Equivocal ... be supplemented with a standardized western blot ... to support a clinical diagnosis of B. ...

The ImmunoWELL Thyroglobulin IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroglobulin in serum and is used as an aid ...

... Screening Panel 6 is an enzyme immunoassay ... autoantibodies against various specific nuclear antigens (SS-A, ... serum, and is used as an aid ... (SLE), mixed connective tissue disease (MCTD), Sjgren's ...

Medicine Products:

ImmunoWELL EBV VCA IgM Test ImmunoDOT Borrelia DotBlot M Test ImmunoWELL Thyroglobulin IgG Quantitative Test ImmunoDOT Autoimmunity Screening Panel 6

Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine D...( ROCKVILLE Md. May 22 /- Novavax I...),Health